- Bausch Health Companies ( NYSE: BHC ) and Glenmark Pharmaceuticals said their nasal spray Ryaltris was approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated eye symptoms in individuals aged 6 years and older.
- The onset of action for nasal symptom relief occurs within 15 minutes after administration of Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), the company said in a Sept. 23 press release.
- BHC -1.96% to $7.01 premarket Sept. 23
For further details see:
Bausch, Glenmark's nasal spray Ryaltris for allergic rhinitis gets approval in Canada